Sector ratings Arrowhead Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 11/09/2024 BST			5-day change	1st Jan Change
20.94 ^USD	-2.47%		-12.68%	-31.57%

09-10	Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	MT
09-10	Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	DJ

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	ESG Refinitiv	Capi. ($)
ARROWHEAD PHARMACEUTICALS, INC.	-	C-	2.6B
REGENERON PHARMACEUTICALS, INC.		B+	123B
VERTEX PHARMACEUTICALS INCORPORATED		B+	123B
ARGENX SE	-	B	32.38B
BIONTECH SE	-	B+	23.6B
BEIGENE, LTD.	-	B	22.43B
GENMAB A/S		A-	16.95B
WUXI APPTEC CO., LTD.		A-	15.37B
INSMED INCORPORATED	-	C	12.5B
SAREPTA THERAPEUTICS, INC.		C+	12.24B
NEUROCRINE BIOSCIENCES, INC.		C+	12.27B
LEGEND BIOTECH CORPORATION	-	D	9.11B
ZEALAND PHARMA A/S	-	B	9.38B
HALOZYME THERAPEUTICS, INC.		A-	7.52B
EXELIXIS, INC.		B	7.6B
PHARMAESSENTIA CORPORATION		-	7.04B
ASCENDIS PHARMA A/S	-	C+	6.48B
Average		B-	26.07B
Weighted average by Cap.		B-